clinical trial · NCT06451497
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaPancreas AdenocarcinomaBiliary Tract CancerProstate CancerUrothelial CarcinomaColorectal CancerTriple Negative Breast CancerZM008
brief summary
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
started
May 22, 2024
primary completion
Dec 1, 2026
completion
Apr 1, 2027
last updated
Apr 2, 2026
official title
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol